BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 20631638)

  • 1. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.
    Au NH; Cheang M; Huntsman DG; Yorida E; Coldman A; Elliott WM; Bebb G; Flint J; English J; Gilks CB; Grimes HL
    J Pathol; 2004 Sep; 204(1):101-9. PubMed ID: 15307143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.
    Sterlacci W; Fiegl M; Hilbe W; Jamnig H; Oberaigner W; Schmid T; Augustin F; Auberger J; Obermann EC; Tzankov A
    J Thorac Oncol; 2010 Sep; 5(9):1325-36. PubMed ID: 20631637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer.
    Ko E; Kim Y; Cho EY; Han J; Shim YM; Park J; Kim DH
    Ann Surg Oncol; 2013 Mar; 20(3):1005-12. PubMed ID: 23115005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
    Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
    J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and clinical significance of apoptosis-related oncogenes in stage I-II non-small cell lung cancer].
    Wang DF; Zeng CG; Lin YB; Hou JH; Zhu ZH
    Ai Zheng; 2006 Mar; 25(3):359-62. PubMed ID: 16536995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)].
    Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Jankowska R
    Pol Merkur Lekarski; 2011 Apr; 30(178):253-8. PubMed ID: 21595169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
    Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
    J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
    Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
    Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
    Gottlin EB; Bentley RC; Campa MJ; Pisetsky DS; Herndon JE; Patz EF
    J Thorac Oncol; 2011 Oct; 6(10):1687-90. PubMed ID: 21642860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
    Brambilla E; Moro D; Gazzeri S; Brambilla C
    J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
    Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
    J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.